Breaking

Week Ahead: NIFTY’s Behavior Against This Level To Influence Trends For The Coming Weeks
AI cameras are giving DC’s air defense a major upgrade
New report warns of growing national security threat to U.S. as China builds AI: ‘Significant and concerning’
DAVID MARCUS: De facto President Trump’s handling of shutdown threat was a masterclass
Trump nominates TV producer, creator of ‘The Apprentice,’ to serve in new administration
Lawmakers react to stopgap funding and averting government shutdown
Trump nominates pair to help lead DOJ, announces Federal Railroad Administration pick
Trump announces newest nominations to lead DOJ, regulate US railroads

Home
Features
- View All On Demos
Buy Now
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

admin

Website

Related Posts

Tech 5: Bitcoin Drops Below US$100,000, Micron Guidance Shakes Investors

December 22, 2024

Stardust Power Acquires Site, Receives Key Permit And Receives Approval For Major Construction To Commence

December 22, 2024

FALCO ANNOUNCES CLOSING OF BROKERED PRIVATE PLACEMENT

December 21, 2024

Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (74)
- Investing (216)
- Politics (245)
- Stocks (81)

Disclaimer: 2morrowgrowth.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2024 2morrowgrowth.com | All Rights Reserved

Top

Type above and press Enter to search. Press Esc to cancel.